Laura Marcos-Kovandzic

Laura Marcos-Kovandzic

Auto-generated profile, based on publicly available information

Laura Marcos-Kovandzic

Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2025 in Cancer Discovery
Verified
Journal Article
Open access
LMLaura Marcos-Kovandzic
Laura Marcos-Kovandzic
MAMichele Avagliano
Michele Avagliano
MKMyriam Ben Khelil
Myriam Ben Khelil
JSJanesa Srikanthan
Janesa Srikanthan
RARim Abdallah
Rim Abdallah
CBCamille Bigenwald
Camille Bigenwald
This study investigates the clinical relevance of the gut microbiome at taxonomic and metabolic levels in anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, both in patients and in a preclinical syngeneic tumor model. Patients with B-cell lymphoma treated with CD19 CAR T cells exhibited profound intestinal dysbiosis, exacerbated after CAR T-cell infusion. This dysbiosis was characterized by low bacterial richness, low soluble MAdCAM-1, and loss of Akkermansia species, associated with resistance to therapy. Mechanistically, oral Akkermansia massiliensis supplementation increased CAR T-cell infiltration into the bone marrow, inverted the CD4/CD8 CAR T-cell ratio, favored Tc1 CD8+ T-cell polarization, and promoted the release of tryptophan-derived indole metabolites, leading to better tumor control. The clinical benefit of Akkermansia spp. supplementation was abolished when CAR T cells were genetically deficient in the indole receptor, aryl hydrocarbon receptor (AhR). AhR-agonistic indoles alone failed to replicate the bacterium’s anticancer effects. These findings suggest that Akkermansia supplementation could improve CAR T-cell potency in patients with intestinal Akkermansia deficiency. Significance: B-cell lymphoma patients treated with CAR T cells harbor major gut microbiota perturbations and related metabolism that restrain CAR T-cell therapy. Reprogramming the gut microbiota ecosystem by oral A. massiliensis supplementation induces CAR T-cell niching and Tc1 differentiation in the bone marrow, promoting tumor control in an AhR-dependent manner.

4 September 2025
Verified
Other
Open access
LMLaura Marcos-Kovandzic
Laura Marcos-Kovandzic
MAMichele Avagliano
Michele Avagliano
MKMyriam Ben Khelil
Myriam Ben Khelil
JSJanesa Srikanthan
Janesa Srikanthan
RARim Abdallah
Rim Abdallah
CBCamille Bigenwald
Camille Bigenwald
Metagenomic raw data at visit 1.

4 September 2025
Verified
Other
Open access
LMLaura Marcos-Kovandzic
Laura Marcos-Kovandzic
MAMichele Avagliano
Michele Avagliano
MKMyriam Ben Khelil
Myriam Ben Khelil
JSJanesa Srikanthan
Janesa Srikanthan
RARim Abdallah
Rim Abdallah
CBCamille Bigenwald
Camille Bigenwald
Metagenomic raw data at visit 3.

4 September 2025
Verified
Other
Open access
LMLaura Marcos-Kovandzic
Laura Marcos-Kovandzic
MAMichele Avagliano
Michele Avagliano
MKMyriam Ben Khelil
Myriam Ben Khelil
JSJanesa Srikanthan
Janesa Srikanthan
RARim Abdallah
Rim Abdallah
CBCamille Bigenwald
Camille Bigenwald
Metagenomic raw data at visit 2.

4 September 2025
Verified
Other
Open access
LMLaura Marcos-Kovandzic
Laura Marcos-Kovandzic
MAMichele Avagliano
Michele Avagliano
MKMyriam Ben Khelil
Myriam Ben Khelil
JSJanesa Srikanthan
Janesa Srikanthan
RARim Abdallah
Rim Abdallah
CBCamille Bigenwald
Camille Bigenwald
Patient characteristics according to Akkermansia spp. prevalence in stool at baseline.

4 September 2025
Verified
Other
Open access
LMLaura Marcos-Kovandzic
Laura Marcos-Kovandzic
MAMichele Avagliano
Michele Avagliano
MKMyriam Ben Khelil
Myriam Ben Khelil
JSJanesa Srikanthan
Janesa Srikanthan
RARim Abdallah
Rim Abdallah
CBCamille Bigenwald
Camille Bigenwald
Table S2 from Gut Microbiota Modulation through Akkermansia spp. Supplementation Increases CAR T-cell Potency